Regeneron Pharmaceuticals Inc. filings document the regulatory disclosures of a biotechnology operating company with marketed medicines, clinical programs and collaboration-driven research activity. Recent Form 8-K reports furnish quarterly and annual financial and operating results, including GAAP and non-GAAP measures, product sales commentary, regulatory and pipeline updates, and acquired in-process research and development charges tied to collaboration, licensing and asset-acquisition activity.
The company's proxy materials cover governance and executive compensation matters, including pay-versus-performance data and equity award disclosures. Regeneron's SEC record also includes exhibit filings and Inline XBRL cover-page data associated with material-event reports, providing formal documentation of financial reporting, corporate governance and capital-allocation disclosures such as share repurchase authorization.
Regeneron Pharmaceuticals (REGN) furnished a press release reporting financial and operating results for the quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated into Securities Act filings unless specifically referenced.
Regeneron Pharmaceuticals expects to record an acquired in-process research and development charge of approximately $83 million on a pre-tax basis in its GAAP and non-GAAP financial results for the third quarter of 2025. This charge primarily reflects a previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement.
The acquired IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share for the third quarter of 2025 by approximately $0.68. Regeneron notes that it does not forecast acquired IPR&D charges because the timing and size of such transactions are uncertain, and it emphasizes that third-quarter 2025 results are preliminary and subject to completion of normal closing procedures.